Annual report
4538.TEDINET S100TRL6
Period2023-04-01 → 2024-03-31
Filed2024-06-25
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 88
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥55.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥51.0bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥49.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥49.3bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥46.9bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥2.2bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.2bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.0bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.8bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.2bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.4bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.6bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥1.5bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥707m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥75.8bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥72.5bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥69.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥69.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥69.2bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥39.1bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥36.8bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥36.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥35.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥34.5bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥33.7bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥32.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.1bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥5.1bn | at 2024-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥8.0bn | at 2023-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥7.3bn | at 2022-03-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥7.1bn | at 2021-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.3bn | at 2020-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥627m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.9bn | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.5bn | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.2bn | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥3.5bn | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥978m | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.5bn | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥14m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥813m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥159.98 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥183.07 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥169.09 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥183.18 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥80.59 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥70 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥4,290.55 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,064.76 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,936.7 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,839.54 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,681.46 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 48.4% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.8% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.8% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.3% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.2% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 9,451,169 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,451,169 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,451,169 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,451,169 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,451,169 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,307 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 1,314 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 1,344 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 1,356 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 1,352 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Businessreportable segment | employees | at 2024-03-31 | 1247 pure |
| Real Estate Businessreportable segment | employees | at 2024-03-31 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,027
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from sales of investment securities inv cf | CurrentYearDuration_NonConsolidatedMember | 84000000 | JPY |
| Other net inv cf | Prior1YearDuration_NonConsolidatedMember | -40000000 | JPY |
| Other net inv cf | CurrentYearDuration_NonConsolidatedMember | -32000000 | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration_NonConsolidatedMember | -1373000000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration_NonConsolidatedMember | -3536000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YearDuration_NonConsolidatedMember | 3536000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYearDuration_NonConsolidatedMember | 4900000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration_NonConsolidatedMember | -3819000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration_NonConsolidatedMember | -3587000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration_NonConsolidatedMember | -3000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration_NonConsolidatedMember | -652000000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration_NonConsolidatedMember | -525000000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration_NonConsolidatedMember | -645000000 | JPY |
| Other net fin cf | Prior1YearDuration_NonConsolidatedMember | -0 | JPY |
| Other net fin cf | CurrentYearDuration_NonConsolidatedMember | -0 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration_NonConsolidatedMember | -813000000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration_NonConsolidatedMember | 14000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration_NonConsolidatedMember | 667000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration_NonConsolidatedMember | -2894000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant_NonConsolidatedMember | 7347000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant_NonConsolidatedMember | 8014000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant_NonConsolidatedMember | 8014000000 | JPY |
| Cash and cash equivalents | CurrentYearInstant_NonConsolidatedMember | 5120000000 | JPY |
| Contract liabilities | Prior1YearInstant_NonConsolidatedMember | 200000000 | JPY |
| Contract liabilities | CurrentYearInstant_NonConsolidatedMember | 62000000 | JPY |
| Medicine department cost of sales inventories | Prior1YearDuration_NonConsolidatedMember | 481000000 | JPY |
| Medicine department cost of sales inventories | CurrentYearDuration_NonConsolidatedMember | 602000000 | JPY |
| Packing and transportation expenses sga | Prior1YearDuration_NonConsolidatedMember | 2208000000 | JPY |
| Packing and transportation expenses sga | CurrentYearDuration_NonConsolidatedMember | 2228000000 | JPY |
| Salaries sga | Prior1YearDuration_NonConsolidatedMember | 2388000000 | JPY |
| Salaries sga | CurrentYearDuration_NonConsolidatedMember | 2354000000 | JPY |
| Provision for bonuses sga | Prior1YearDuration_NonConsolidatedMember | 398000000 | JPY |
| Provision for bonuses sga | CurrentYearDuration_NonConsolidatedMember | 384000000 | JPY |
| Provision for directors bonuses sga | Prior1YearDuration_NonConsolidatedMember | 21000000 | JPY |
| Provision for directors bonuses sga | CurrentYearDuration_NonConsolidatedMember | 20000000 | JPY |
| Provision for directors retirement benefits sga | Prior1YearDuration_NonConsolidatedMember | 11000000 | JPY |
| Provision for directors retirement benefits sga | CurrentYearDuration_NonConsolidatedMember | 8000000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration_NonConsolidatedMember | 326000000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration_NonConsolidatedMember | 279000000 | JPY |
| Depreciation sga | Prior1YearDuration_NonConsolidatedMember | 379000000 | JPY |
| Depreciation sga | CurrentYearDuration_NonConsolidatedMember | 321000000 | JPY |
| Research and development expenses sga | Prior1YearDuration_NonConsolidatedMember | 1353000000 | JPY |
| Research and development expenses sga | CurrentYearDuration_NonConsolidatedMember | 1469000000 | JPY |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period | Prior1YearDuration_NonConsolidatedMember | 1353000000 | JPY |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period | CurrentYearDuration_NonConsolidatedMember | 1469000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-06-25 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第101期(自 2023年４月１日 至 2024年３月31日) |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |